The expression of the TXNRD1 gene was also associated with increases in the resistance of multiple drugs, including tamoxifen (for treating breast cancer), imexon (for treating skin cancer), carmustine (for treating osteoma and non-small-cell lung cancer), raloxifene (for treating breast cancer), hypothemycin (for treating thyroid cancer, colon cancer, and melanoma), and arsenic trioxide (for treating leukemia). This evidence concerns the gene TXNRD1 and colonic neoplasm.